Hiken, J F
McDonald, J I
Decker, K F
Sanchez, C
Hoog, J
VanderKraats, N D
Jung, K L
Akinhanmi, M
Rois, L E
Ellis, M J
Edwards, J R
Article History
Received: 10 March 2016
Revised: 7 September 2016
Accepted: 8 September 2016
First Online: 21 November 2016
Competing interests
: Dr Ellis has received consulting fees from Pfizer, Novartis and AstraZenica. He has ownership and patent income from Bioclassifier LLC for the PAM50 breast cancer test Prosigna sold by Nanostring. The remaining authors declare no conflict of interest.